|
1
|
Cao M, Ren Y, Li Y, Deng J, Su X, Tang Y,
Yuan F, Deng H, Yang G, He Z, et al: Lnc-ZEB2-19 inhibits the
progression and lenvatinib resistance of hepatocellular carcinoma
by attenuating the NF-κB signaling pathway through the TRA2A/RSPH14
axis. Int J Biol Sci. 19:3678–3693. 2023.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kanwal F and Singal AG: Surveillance for
hepatocellular carcinoma: Current best practice and future
direction. Gastroenterology. 157:54–64. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Li CM, Zhang J, Wu W, Zhu Z, Li F, Wu D,
Wang XJ, Xie CM and Gong JP: FBXO43 increases CCND1 stability to
promote hepatocellular carcinoma cell proliferation and migration.
Front Oncol. 13(1138348)2023.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Liu Y, Yao Y, Liao B, Zhang H, Yang Z, Xia
P, Jiang X, Ma W, Wu X, Mei C, et al: A positive feedback loop of
CENPU/E2F6/E2F1 facilitates proliferation and metastasis via
ubiquitination of E2F6 in hepatocellular carcinoma. Int J Biol Sci.
18:4071–4087. 2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Yin Z, Dong C, Jiang K, Xu Z, Li R, Guo K,
Shao S and Wang L: Heterogeneity of cancer-associated fibroblasts
and roles in the progression, prognosis, and therapy of
hepatocellular carcinoma. J Hematol Oncol. 12(101)2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Walker RG, Poggioli T, Katsimpardi L,
Buchanan SM, Oh J, Wattrus S, Heidecker B, Fong YW, Rubin LL, Ganz
P, et al: Biochemistry and biology of GDF11 and myostatin:
Similarities, differences, and questions for future investigation.
Circ Res. 118:1125–1142. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bajikar SS, Wang CC, Borten MA, Pereira
EJ, Atkins KA and Janes KA: Tumor-suppressor inactivation of GDF11
occurs by precursor sequestration in triple-negative breast cancer.
Dev Cell. 43:418–435.e13. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Gao H, He Z, Gao C, Liu N, Zhang Z, Niu W,
Niu J and Peng C: Exosome-transmitted miR-3124-5p promotes
cholangiocarcinoma development via targeting GDF11. Front Oncol.
12(936507)2022.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ungaro F, Colombo P, Massimino L, Ugolini
GS, Correale C, Rasponi M, Garlatti V, Rubbino F, Tacconi C,
Spaggiari P, et al: Lymphatic endothelium contributes to colorectal
cancer growth via the soluble matrisome component GDF11. Int J
Cancer. 145:1913–1920. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Liu Y, Shao L, Chen K, Wang Z, Wang J,
Jing W and Hu M: GDF11 restrains tumor growth by promoting
apoptosis in pancreatic cancer. Onco Targets Ther. 11:8371–8379.
2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Frohlich J, Kovacovicova K, Raffaele M,
Virglova T, Cizkova E, Kucera J, Bienertova-Vasku J, Wabitsch M,
Peyrou M, Bonomini F, et al: GDF11 inhibits adipogenesis and
improves mature adipocytes metabolic function via WNT/β-catenin and
ALK5/SMAD2/3 pathways. Cell Prolif. 55(e13310)2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Frohlich J, Mazza T, Sobolewski C, Foti M
and Vinciguerra M: GDF11 rapidly increases lipid accumulation in
liver cancer cells through ALK5-dependent signaling. Biochim
Biophys Acta Mol Cell Biol Lipids. 1866(158920)2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zhang YH, Pan LH, Pang Y, Yang JX, Lv MJ,
Liu F, Qu XF, Chen XX, Gong HJ, Liu D and Wei Y: GDF11/BMP11 as a
novel tumor marker for liver cancer. Exp Ther Med. 15:3495–3500.
2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Gerardo-Ramirez M, Lazzarini-Lechuga R,
Hernandez-Rizo S, Hernández-Rizo S, Jiménez-Salazar JE,
Simoni-Nieves A, García-Ruiz C, Fernández-Checa JC, Marquardt JU,
Coulouarn C, Gutiérrez-Ruiz MC, et al: GDF11 exhibits tumor
suppressive properties in hepatocellular carcinoma cells by
restricting clonal expansion and invasion. Biochim Biophys Acta Mol
Basis Dis. 1865:1540–1554. 2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Battaglioni S, Benjamin D, Wälchli M,
Maier T and Hall MN: mTOR substrate phosphorylation in growth
control. Cell. 185:1814–1836. 2022.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Han X, Goh KY, Lee WX, Choy SM and Tang
HW: The importance of mTORC1-autophagy axis for skeletal muscle
diseases. Int J Mol Sci. 24(297)2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hernandez S, Simoni-Nieves A,
Gerardo-Ramirez M, Torres S, Fucho R, Gonzalez J, Castellanos-Tapia
L, Hernández-Pando R, Tejero-Barrera E, Bucio L, et al: GDF11
restricts aberrant lipogenesis and changes in mitochondrial
structure and function in human hepatocellular carcinoma cells. J
Cell Physiol. 236:4076–4090. 2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Saxton RA and Sabatini DM: mTOR signaling
in growth, metabolism, and disease. Cell. 168:960–976.
2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Chung CY, Shin HR, Berdan CA, Ford B, Ward
CC, Olzmann JA, Zoncu R and Nomura DK: Covalent targeting of the
vacuolar H+-ATPase activates autophagy via mTORC1
inhibition. Nat Chem Biol. 15:776–785. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
23
|
Wendong Y, Jiali J, Qiaomei F, Yayun W,
Xianze X, Zheng S and Wei H: Biomechanical forces and
force-triggered drug delivery in tumor neovascularization. Biomed
Pharmacother. 171(116117)2024.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Anwanwan D, Singh SK, Singh S, Saikam V
and Singh R: Challenges in liver cancer and possible treatment
approaches. Biochim Biophys Acta Rev Cancer.
1873(188314)2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Lee YS, Jeong S, Kim KY, Yoon JS, Kim S,
Yoon KS, Ha J, Kang I and Choe W: Honokiol inhibits hepatoma
carcinoma cell migration through downregulated Cyclophilin B
expression. Biochem Biophys Res Commun. 552:44–51. 2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Li T, Zhong J, Dong X, Xiu P, Wang F, Wei
H, Wang X, Xu Z, Liu F, Sun X and Li J: Meloxicam suppresses
hepatocellular carcinoma cell proliferation and migration by
targeting COX-2/PGE2-regulated activation of the β-catenin
signaling pathway. Oncol Rep. 35:3614–3622. 2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Mandell MA, Saha B and Thompson TA: The
tripartite nexus: Autophagy, cancer, and tripartite
motif-containing protein family members. Front Pharmacol.
11(308)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Poillet-Perez L and White E: Role of tumor
and host autophagy in cancer metabolism. Genes Dev. 33:610–619.
2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Cao Z, Zhang H, Cai X, Fang W, Chai D, Wen
Y, Chen H, Chu F and Zhang Y: Luteolin promotes cell apoptosis by
inducing autophagy in hepatocellular carcinoma. Cell Physiol
Biochem. 43:1803–1812. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Wang XK, Liao XW, Zhou X, Han CY, Chen ZJ,
Yang CK, Huang JL, Wang JY, Liu JQ, Huang HS, et al: Oncogene UBE2I
enhances cellular invasion, migration and proliferation abilities
via autophagy-related pathway resulting in poor prognosis in
hepatocellular carcinoma. Am J Cancer Res. 10:4178–4197.
2020.PubMed/NCBI
|
|
31
|
Qiao L, Zhang Q, Sun Z, Liu Q, Wu Z, Hu W,
Bao S, Yang Q and Liu L: The E2F1/USP11 positive feedback loop
promotes hepatocellular carcinoma metastasis and inhibits autophagy
by activating ERK/mTOR pathway. Cancer Lett. 514:63–78.
2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Wang C, Wang X, Su Z, Fei H, Liu X and Pan
Q: The novel mTOR inhibitor Torin-2 induces autophagy and
downregulates the expression of UHRF1 to suppress hepatocarcinoma
cell growth. Oncol Rep. 34:1708–1716. 2015.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Zhao M, Ying L, Wang R, Yao J, Zhu L,
Zheng M, Chen Z and Yang Z: DHX15 inhibits autophagy and the
proliferation of hepatoma cells. Front Med (Lausanne).
7(591736)2021.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Choi YJ, Park YJ, Park JY, Jeong HO, Kim
DH, Ha YM, Kim JM, Song YM, Heo HS, Yu BP, et al: Inhibitory effect
of mTOR activator MHY1485 on autophagy: Suppression of lysosomal
fusion. PLoS One. 7(e43418)2012.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Zhou T, Liu L, Lan H and Fang D: Effects
of LAIR-1 on hepatocellular carcinoma cell proliferation and
invasion via PI3K-AKT-mTOR pathway regulation. Immun Inflamm Dis.
11(e982)2023.PubMed/NCBI View
Article : Google Scholar
|
|
36
|
Liao ZZ, Deng Q, Xiao F, Xie M and Tang
XQ: Spermidine inhibits high glucose-induced endoplasmic reticulum
stress in HT22 cells by upregulation of growth differentiation
factor 11. Neuroreport. 33:819–827. 2022.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Yue F, Li W, Zou J, Jiang X, Xu G, Huang H
and Liu L: Spermidine prolongs lifespan and prevents liver fibrosis
and hepatocellular carcinoma by activating MAP1S-mediated
autophagy. Cancer Res. 77:2938–2951. 2017.PubMed/NCBI View Article : Google Scholar
|
